Top Markets
Coin of the day
Sesen Bio, Inc. Sesen Bio, Inc.

Sesen Bio, Inc.

SESN
株式のランク #34230
Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the... Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the creation, advancement, and eventual market launch of targeted fusion protein therapeutics (TFPTs). Their primary aim is to combat various forms of cancer. Their flagship experimental drug, Vicineum, is a locally administered targeted fusion protein currently undergoing Phase III clinical trials. It targets several conditions, including non-muscle invasive bladder cancer that has not responded to bacillus Calmette-Guérin (BCG) treatment, non-muscle invasive carcinoma in situ of the bladder in patients who previously received BCG, and squamous cell carcinoma affecting the head and neck region. Another promising candidate, VB6-845d, is being developed to address a range of anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio is also collaborating with Leiden University Medical Center on the joint development of an imaging agent. Originally incorporated in 2008, the company operated as Eleven Biotherapeutics, Inc. before rebranding as Sesen Bio, Inc. in May 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
株価
$0.6288
最終同期: 2023-03-07
時価総額
$6.00M
変化(1日)
7.29%
変化(1年)
0.00%
US
取引 Sesen Bio, Inc. (SESN)

カテゴリー

Sesen Bio, Inc.(SESN)の株価履歴
終値の最高値: $0.60 (2023-03-01)

終値の最安値: $2.23 (2018-05-01)
Sesen Bio, Inc. の株価履歴(2018 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2023 14.86%
2022 -41.73%
2021 -39.18%
2020 40.29%
2019 -22.75%
2018 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE